(Laughter) Because now, we've shared this molecule, just since December of last year, with 40 laboratories in the United States and 30 more in Europe -- many of them pharmaceutical companies, seeking now to enter this space, to target this rare cancer that, thankfully right now, is quite desirable to study in that industry.
Porque agora que xa compartimos a molécula, en decembro do ano pasado, con 40 laboratorios nos EEUU e outros 30 en Europa, moitos deles de empresas farmacéuticas procuran agora entrar neste espazo, en investigar sobre este cancro; agora, por fortuna, resulta interesante tratar o tema na industria.